NEW HAVEN, Conn., May 28, 2025 - Biohaven Ltd. $(BHVN)$, a clinical-stage biopharmaceutical company, has announced plans to initiate pivotal trials for their drug candidates in the treatment of Graves' Disease and IgA nephropathy. The trials are set to begin in the second half of 2025 and the first half of 2026, respectively. During their recent R&D Day, Biohaven highlighted the success of their MoDE™ and TRAP™ degraders, specifically BHV-1300 and BHV-1400, which have shown significant selectivity and efficacy in early studies. BHV-1400, designed for IgA nephropathy, has achieved over 80% sustained reductions in galactose-deficient IgA1 levels, demonstrating potential as a first-in-class treatment. The drug was well-tolerated in Phase 1 trials, with most adverse events reported as mild and self-resolving. Biohaven's focus remains on advancing precision therapies for immune-mediated diseases.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.